PRIVETERRA ACQUISITION CORP. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01 Regulation FD Disclosure.

On February 14, 2023, AEON Biopharma, Inc. ("AEON") issued a press release announcing that AEON will host a key opinion leader webinar on the past, present, and potential future treatments for migraine using botulinum toxin on Friday, February 24, 2023 at 11:00 a.m. Eastern Time. A copy of the press release is furnished hereto as Exhibit 99.1.

The information in this Item 7.01, including Exhibit 99.1, is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to liabilities under that section, and shall not be deemed to be incorporated by reference into the filings of PMGM under the Securities Act of 1933, as amended (the "Securities Act") or the Exchange Act, regardless of any general incorporation language in such filings. This Current Report on Form 8-K will not be deemed an admission as to the materiality of any information of the information contained in this Item 7.01, including Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits



                                       2





Exhibit
  No.                                    Description

  99.1       Press Release, dated February 14, 2023
104        The cover page from this Current Report on Form 8-K, formatted in
           Inline XBRL.




                                       3

© Edgar Online, source Glimpses